• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

    10/30/24 7:00:00 AM ET
    $BPMC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPMC alert in real time by email

    -- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 --

    -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 --

    --  On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end --

    CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.

    Blueprint Medicines logo (PRNewsfoto/Blueprint Medicines Corporation)

    "With another strong quarter of AYVAKIT revenue performance, our year-to-date results provide the foundation to drive significant growth and long-term shareholder value creation in 2025 and beyond. AYVAKIT's sales momentum has given us the confidence to raise our revenue expectations again this year, estimating that we will end the year between $475 million and $480 million dollars. Ending our first full year of launch at nearly half a billion dollars in revenue positions AYVAKIT to be one of the most successful rare disease launches to-date," said Kate Haviland, Chief Executive Officer of Blueprint Medicines. "AYVAKIT has demonstrated tangible benefits to patients globally, with long-term data further reinforcing the clinically meaningful benefits and well-tolerated profile of a disease-modifying treatment. AYVAKIT's strong revenue ramp coupled with disciplined investment in our most compelling product opportunities, places Blueprint Medicines in a position to realize the significant decline in cash burn this year, while maintaining our focus on long-term growth and value creation."

    Third Quarter 2024 Highlights and Recent Progress

    Mast cell disorders

    • Achieved AYVAKIT net product revenues of $128.2 million for third quarter of 2024, including $113.1 million in the US and $15.1 million ex-US, representing 136 percent growth year-over-year.
    • Advanced the Phase 1 single ascending dose/multiple ascending dose healthy volunteer study of BLU-808, a highly selective and potent investigational oral wild-type KIT inhibitor, with best-in-class potential for chronic urticaria and other mast cell disorders. Data from the healthy volunteer study, including safety, pharmacokinetic and pharmacodynamic markers, are anticipated in early 2025.
    • Presented data at the American College of Allergy, Asthma and Immunology (ACAAI) conference demonstrating the efficacy of AYVAKIT in patients with moderate and severe indolent SM (ISM) at baseline, and showing the significant disease burden of SM, highlighting the urgency to diagnose and treat. Read the presentations here.
    • Hosting scientific seminar on mast cell franchise development with leading allergy and asthma expert Dr. Paul O'Byrne on Thursday, November 14, 2024.

    2024 Financial Guidance

    Blueprint Medicines now anticipates approximately $475 million to $480 million in global AYVAKIT net product revenues in 2024, an increase from the previous range of $435 million to $450 million. This updated guidance is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger than expected performance outside of the U.S. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a durable capital position to achieve a self-sustainable financial profile.

    Key Upcoming Milestones

    The company plans to achieve the following remaining milestones by the end of 2024:

    Mast cell disorders

    • Initiate registration-enabling Part 2 of the HARBOR trial of elenestinib in ISM by the end of this year.

    Cell cycle inhibition

    • Continue strategic business development discussions.
    • Complete Phase 1 combination dose escalation for BLU-222 by end of year to inform registration plans.

    Third Quarter 2024 Results

    • Revenues: Revenues were $128.2 million for the third quarter of 2024 generated from the net product sales of AYVAKIT/AYVAKYT. Revenues were $56.6 million in the third quarter of 2023, including $54.2 million of net product revenues from sales of AYVAKIT/AYVAKYT and $2.4 million in collaboration, license and other revenues.
    • Cost of Sales: Cost of sales was $1.9 million for the third quarter of 2024, as compared to $2.8 million for the third quarter of 2023. The decrease was primarily due to lower sales to our collaboration partner in greater China.
    • R&D Expenses: Research and development expenses were $85.3 million for the third quarter of 2024, as compared to $110.3 million for the third quarter of 2023. This decrease was primarily due to operational efficiency across our portfolio as we execute across our top priority programs and the timing of manufacturing of clinical trial materials. Research and development expenses included $12.6 million in stock-based compensation expenses for the third quarter of 2024.
    • SG&A Expenses: Selling, general and administrative expenses were $89.9 million for the third quarter of 2024, as compared to $70.7 million for the third quarter of 2023. This increase was primarily due to an increase in activities supporting the commercialization of AYVAKIT/AYVAKYT. Selling, general, and administrative expenses included $15.7 million in stock-based compensation expenses for the third quarter of 2024.
    • Net Loss: Net loss was $56.3 million for the third quarter of 2024, as compared to a net loss of $133.7 million for the third quarter of 2023.
    • Cash Position: As of September 30, 2024, cash, cash equivalents and investments were $882.4 million, as compared to $767.2 million as of December 31, 2023. Blueprint Medicines' cash and investments provide a durable capital position which, together with anticipated product revenues, the company believes will enable it to reach a self-sustainable financial profile.

    Conference Call Information

    Blueprint Medicines will host a live conference call and webcast at 8:00 a.m. ET today to discuss third quarter 2024 financial results and recent business activities. The conference call may be accessed by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and referring conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

    Upcoming Investor Conferences 

    Blueprint Medicines will participate in three upcoming investor conferences:

    • Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 3:30 p.m. ET.
    • Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:20 a.m. ET.
    • Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 12:00 noon GMT.

    Scientific Webinar Series

    • Blueprint Medicines will host the second event in its scientific seminar series, focused on mast cell diseases, on Thursday, November 14th at 10:00 a.m. ET.

    A live webcast of the above presentations and any related slides will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on the Blueprint Medicines website following the events.

    About Blueprint Medicines

    Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' operations, including its expectations regarding growth and net product revenue in 2024; statements regarding its current or future approved drugs and drug candidates and operations, including plans to initiate registration-enabling Part 2 of the HARBOR trial of elenestinib in ISM in 2024, complete Phase 1 combination dose escalation for BLU-222 to inform registration plans and continue strategic business development discussions by the end of 2024, and present healthy volunteer data from its Phase 1 trial for BLU-808 in early 2025; expectations related to the markets for current or future approved drugs and drug candidates, including expectations regarding the size or scale of patient opportunities that future approved drugs and drug candidates could address; the potential benefits of any of its current or future approved drugs or drug candidates in treating patients; statements related to liquidity and capital position, including expectations that its cash, cash equivalents and investments will provide a durable capital position which, together with anticipated product revenues, will enable Blueprint Medicines to reach a self-sustainable financial profile; and its financial performance, strategy, goals and anticipated milestones, business plans and focus, including expectations regarding its revenue ramp and continued decline in operating expenses and cash burn. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the risk that the marketing and sale of AYVAKIT/ AYVAKYT or any future approved drugs may be unsuccessful or less successful than anticipated, or that AYVAKIT/ AYVAKYT may not gain market acceptance by physicians, patients, third-party payors and others in the medical community; the risk that the market opportunities for AYVAKIT/ AYVAKYT or Blueprint Medicines' drug candidates are smaller than we estimate or that any approval we obtain may be based on a narrower definition of the patient population that we anticipate; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect its approved drugs or its current or future drug candidates, including affecting the initiation, timing and progress of clinical trials; risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing and other arrangements; risks related to its liquidity and financial position, including the risk that Blueprint Medicines may be unable to generate sufficient future product revenues to achieve and maintain a self-sustainable financial profile; and the accuracy of its estimates of revenues, expenses and capital requirements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

    Trademarks

    Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

    Blueprint Medicines Corporation

    Selected Condensed Consolidated Balance Sheet Data

    (in thousands)

    (unaudited)

















    September 30,



    December 31,





    2024



    2023

    Cash, cash equivalents and investments

    $

    882,353



    $

    767,171

    Working capital (1)



    597,187





    593,470

    Total assets



    1,199,649





    1,049,250

    Deferred revenue (2)



    12,034





    5,604

    Liability related to the sale of future royalties and revenues (2)



    261,207





    441,625

    Term loan (2)



    386,569





    238,813

    Total liabilities



    886,501





    918,641

    Total stockholders' equity



    313,148





    130,609



    (1)   Blueprint Medicines defines working capital as current assets less current liabilities.

    (2)   Includes both current and long-term portions of the balance.

     

    Blueprint Medicines Corporation

    Condensed Consolidated Statements of Operations Data

    (in thousands, except per share data)

    (unaudited)







    Three Months Ended



    Nine Months Ended





    September 30,



    September 30,





    2024



    2023



    2024



    2023

    Revenues:

























    Product revenue, net



    $

    128,184



    $

    54,228



    $

    334,825



    $

    133,173

    Collaboration, license and other revenue





    —





    2,338





    27,633





    44,250

    Total revenues





    128,184





    56,566





    362,458





    177,423

    Cost and operating expenses:

























    Cost of sales





    1,932





    2,782





    12,716





    8,280

    Collaboration loss sharing





    —





    1,771





    —





    4,301

    Research and development





    85,300





    110,252





    257,761





    330,184

    Selling, general and administrative





    89,926





    70,741





    262,822





    215,826

    Total cost and operating expenses





    177,158





    185,546





    533,299





    558,591

    Other income (expense):

























    Interest expense, net





    (7,616)





    (3,808)





    (20,376)





    (13,624)

    Other income (expense), net





    587





    (728)





    962





    (369)

    Debt extinguishment gain





    —





    —





    173,676





    —

    Total other income (expense), net





    (7,029)





    (4,536)





    154,262





    (13,993)

    Loss before income taxes





    (56,003)





    (133,516)





    (16,579)





    (395,161)

    Income tax expense





    273





    197





    554





    907

    Net Loss



    $

    (56,276)



    $

    (133,713)



    $

    (17,133)



    $

    (396,068)

    Net Loss per share — basic and diluted



    $

    (0.89)



    $

    (2.20)



    $

    (0.27)



    $

    (6.55)

    Weighted-average number of common

    shares used in net loss per share —

    basic and diluted





    63,381





    60,688





    62,608





    60,445

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-reports-third-quarter-2024-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302290815.html

    SOURCE Blueprint Medicines Corporation

    Get the next $BPMC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What were the net product revenues for AYVAKIT in the third quarter of 2024?

      Blueprint Medicines reported $128.2 million in AYVAKIT net product revenues for Q3 2024, including $113.1 million from the US and $15.1 million from international markets, representing a 136% year-over-year growth.

    • What is the updated revenue guidance for AYVAKIT for 2024?

      The revenue guidance for AYVAKIT has been raised to a range of approximately $475 million to $480 million for the year 2024, up from the previous estimate of $435 million to $450 million.

    • What are the key upcoming milestones for Blueprint Medicines by the end of 2024?

      Blueprint Medicines aims to initiate the registration-enabling Part 2 of the HARBOR trial of elenestinib in ISM by the end of 2024.

    • What is the cash position of Blueprint Medicines as of September 30, 2024?

      The company's cash, cash equivalents, and investments stood at $882.4 million as of September 30, 2024, compared to $767.2 million at the end of December 2023, providing a strong capital position for sustaining operations.

    • What was the net loss reported by Blueprint Medicines for Q3 2024?

      The net loss for the third quarter 2024 was $56.3 million, significantly improved from a net loss of $133.7 million in the same quarter of 2023.

    Recent Analyst Ratings for
    $BPMC

    DatePrice TargetRatingAnalyst
    3/20/2025$100.00Equal-Weight
    Morgan Stanley
    3/18/2025Outperform
    Wolfe Research
    3/17/2025$135.00Buy
    Jefferies
    3/7/2025$150.00Sector Outperform
    Scotiabank
    11/14/2024$126.00Overweight
    JP Morgan
    10/24/2024$88.00Neutral
    UBS
    5/14/2024$140.00Overweight
    Stephens
    5/6/2024$50.00 → $97.00Underperform → Market Perform
    Leerink Partners
    More analyst ratings

    $BPMC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

      CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET. A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation. About Blueprint Medicine

      3/31/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Rossi Christina sold $231,386 worth of shares (2,274 units at $101.75), decreasing direct ownership by 3% to 66,992 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      5/7/25 4:32:25 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRINCIPAL ACCOUNTING OFFICER Hurley Ariel exercised 2,752 shares at a strike of $54.13 and sold $283,819 worth of shares (2,752 units at $103.13) (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      5/7/25 4:30:51 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Haviland Kate sold $216,461 worth of shares (2,498 units at $86.65), decreasing direct ownership by 1% to 165,929 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      4/3/25 4:30:32 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Financials

    Live finance-specific insights

    See more
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

      -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass., Feb. 13, 2025 /PRNewswire/ -- Blueprint Medici

      2/13/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Leadership Updates

    Live Leadership Updates

    See more
    • Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

      -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases. The submission includes data from the registrationa

      11/22/22 4:36:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

      Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar

      8/8/22 6:15:00 AM ET
      $BPMC
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

      -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpos

      7/14/22 4:15:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Blueprint Medicines with a new price target

      Morgan Stanley resumed coverage of Blueprint Medicines with a rating of Equal-Weight and set a new price target of $100.00

      3/20/25 7:59:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Blueprint Medicines

      Wolfe Research initiated coverage of Blueprint Medicines with a rating of Outperform

      3/18/25 7:49:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Blueprint Medicines with a new price target

      Jefferies initiated coverage of Blueprint Medicines with a rating of Buy and set a new price target of $135.00

      3/17/25 7:24:14 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Blueprint Medicines Corporation

      10-Q - Blueprint Medicines Corp (0001597264) (Filer)

      5/1/25 4:19:40 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Blueprint Medicines Corp (0001597264) (Filer)

      5/1/25 7:12:39 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Blueprint Medicines Corporation

      DEFA14A - Blueprint Medicines Corp (0001597264) (Filer)

      4/24/25 4:20:51 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Blueprint Medicines Corporation

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      11/14/24 1:22:36 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      4/10/24 12:58:49 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      2/14/24 10:03:02 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care